Drug Type Antibody drug conjugate (ADC) |
Synonyms- |
Target |
Mechanism DNA inhibitors(DNA inhibitors), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), DNA cross linking agents |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC8H16N2O3 |
InChIKeyHSRXSKHRSXRCFC-WDSKDSINSA-N |
CAS Registry27493-61-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | US | 18 May 2017 | |
Advanced Malignant Solid Neoplasm | Phase 1 | BE | 18 May 2017 | |
Bladder Cancer | Phase 1 | US | 18 May 2017 | |
Bladder Cancer | Phase 1 | BE | 18 May 2017 | |
Breast Cancer | Phase 1 | US | 18 May 2017 | |
Breast Cancer | Phase 1 | BE | 18 May 2017 | |
Malignant neoplasm of gastro-oesophageal junction | Phase 1 | US | 18 May 2017 | |
Malignant neoplasm of gastro-oesophageal junction | Phase 1 | BE | 18 May 2017 | |
Non-Small Cell Lung Cancer | Phase 1 | US | 18 May 2017 | |
Non-Small Cell Lung Cancer | Phase 1 | BE | 18 May 2017 |
Phase 1 | 21 | (Part 1: Dose 30μg/kg) | djgjblbsom(cjengowbtl) = iquoxvcuno xnvwvahcqa (csguivdeid, mcledygvwg - whrxfxjlyd) View more | - | 28 Aug 2019 | ||
(Part 1: Dose 60μg/kg) | djgjblbsom(cjengowbtl) = yvgohwfbxj xnvwvahcqa (csguivdeid, hqlxnzjqgr - yazyqpjhhj) View more |